Immumem is ending the "guess-and-check" era of oncology by bridging the gap between Bio-IT and cellular persistence. We replace the current transient "sprint" therapies against cancers with "Marathon Sentinels"-iPSC-derived memory cells engineered with 10+ edits to hunt relapse 10-times longer than current approaches. Using our VIVO-IQ engine, we predict clinical success with >90% accuracy, cutting costs by 90%. We turn hospital losses into profit, making a cure globally scalable.